Market Overview

OvaScience Soars 35% Amid Positive Corporate Goals, Wedbush Upgrade

Related OVAS
Mid-Afternoon Market Update: Bed Bath & Beyond Drops After Weak Q3 Results; Tokai Pharmaceuticals Shares Surge
12 Biggest Mid-Day Losers For Thursday
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In ... (GuruFocus)

Shares of OvaScience Inc (NASDAQ: OVAS) soared over 35 percent Thursday following its announcement on Wednesday that it achieved its 2014 corporate goals.

The company is advancing the AUGMENTSM, OvaPrimeSM and OvaTureSM treatments for patients in need of new fertility treatment options.

The company indicated that its OvaPrime Treatment will be introduced into select international IVF Clinics by the end of 2015.

Amid the positive news, Wedbush Securities upgraded the stock from Neutral to Outperform and boosted the price target from $22 to $47.

OvaScience recently traded at $47.82, up 33.9 percent.

Latest Ratings for OVAS

Aug 2016JP MorganMaintainsNeutral
Jan 2016OppenheimerDowngradesOutperformPerform
Jan 2016Credit SuisseInitiates Coverage onUnderperform

View More Analyst Ratings for OVAS
View the Latest Analyst Ratings

Posted-In: WedbushNews Upgrades Price Target Analyst Ratings


Related Articles (OVAS)

View Comments and Join the Discussion!